TY - JOUR
T1 - Hemodynamic responses to atrial natriuretic factor in nephrectomized rabbits
T2 - Attenuation of the circulatory consequences of acute volume expansion
AU - Volpe, M.
AU - Vecchione, F.
AU - Cuocolo, A.
AU - Lembo, G.
AU - Pignalosa, S.
AU - Condorelli, M.
AU - Trimarco, B.
PY - 1988
Y1 - 1988
N2 - We investigated the hemodynamic responses to three doses of atrial natriuretic factor [human atrial natriuretic factor-(99-126)] (ANF) in nephrectomized rabbits anesthetized with ketamine and acepromazine. The influence of the different doses of the peptide on the hemodynamic consequences produced by acute volume expansion (0.9% NaCl, 1.4 ml/kg/min for 60 minutes) was also studied. All three dosages of ANF (0.001, 0.01. and 0.2 μg/kg/min for 20 minutes) significantly reduced blood pressure. With the lowest dose, the hypotensive effect was associated with reduction in systemic vascular resistance and no significant change in heart rate, stroke volume, central venous pressure, and hematocrit. In contrast, the intermediate and high doses, which resulted in markedly higher plasma levels, caused a significant decrease in heart rate, central venous pressure, and stroke volume; a slight rise in hematocrit; and no change in systemic vascular resistance. Volume expansion produced by saline infusion in an additional group of nephrectomized rabbits increase central venous pressure and decreased hematocrit. When ANF infusion was associated to volume expansion, each dosage of ANF was able to reduce the rise in central venous pressure, while only the higher dosage attenuated the progressive fall in hematocrit caused by volume expansion. Plasma volume, measured at the end of volume expansion was lower in the group treated with the highest dose of ANF than in the control animals (28.2 ± 9 vs. 35.1 ± 3 ml/kg, p <0.05). We conclude that 1) ANF induces significant hemodynamic effects independently from its renal action. These effects vary qualitatively according to the circulating levels achieved with the different dosages. 2) The administration of the peptide attenuate the hemodynamic consequences of acute volume overload.
AB - We investigated the hemodynamic responses to three doses of atrial natriuretic factor [human atrial natriuretic factor-(99-126)] (ANF) in nephrectomized rabbits anesthetized with ketamine and acepromazine. The influence of the different doses of the peptide on the hemodynamic consequences produced by acute volume expansion (0.9% NaCl, 1.4 ml/kg/min for 60 minutes) was also studied. All three dosages of ANF (0.001, 0.01. and 0.2 μg/kg/min for 20 minutes) significantly reduced blood pressure. With the lowest dose, the hypotensive effect was associated with reduction in systemic vascular resistance and no significant change in heart rate, stroke volume, central venous pressure, and hematocrit. In contrast, the intermediate and high doses, which resulted in markedly higher plasma levels, caused a significant decrease in heart rate, central venous pressure, and stroke volume; a slight rise in hematocrit; and no change in systemic vascular resistance. Volume expansion produced by saline infusion in an additional group of nephrectomized rabbits increase central venous pressure and decreased hematocrit. When ANF infusion was associated to volume expansion, each dosage of ANF was able to reduce the rise in central venous pressure, while only the higher dosage attenuated the progressive fall in hematocrit caused by volume expansion. Plasma volume, measured at the end of volume expansion was lower in the group treated with the highest dose of ANF than in the control animals (28.2 ± 9 vs. 35.1 ± 3 ml/kg, p <0.05). We conclude that 1) ANF induces significant hemodynamic effects independently from its renal action. These effects vary qualitatively according to the circulating levels achieved with the different dosages. 2) The administration of the peptide attenuate the hemodynamic consequences of acute volume overload.
UR - http://www.scopus.com/inward/record.url?scp=0023712332&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023712332&partnerID=8YFLogxK
M3 - Article
C2 - 2969306
AN - SCOPUS:0023712332
VL - 63
SP - 322
EP - 329
JO - Circulation Research
JF - Circulation Research
SN - 0009-7330
IS - 2
ER -